A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection

This study has been completed.
Sponsor:
Information provided by:
Genzyme, a Sanofi Company
ClinicalTrials.gov Identifier:
NCT00089947
First received: August 18, 2004
Last updated: August 10, 2012
Last verified: August 2012
  Purpose

This study involves the use of a drug called Thymoglobulin, which is approved in the US to treat kidney transplant rejection and in Canada to treat and to prevent kidney transplant rejection.

This study will evaluate the effect of Thymoglobulin and reduced doses of steroids to prevent renal transplant rejection and will provide a basis for future evaluations of Thymoglobulin as an immunosuppressive agent to help prevent renal transplant rejection.

Subjects meeting all inclusion and exclusion criteria are eligible to participate in this study. In addition to standard treatment, study participants will receive either Thymoglobulin with rapid discontinuation of steroids or steroids per hospital standards for at least the first 90 days after transplant. The treatment assignment is random and is not chosen by the subject or their physician.

Subjects will be monitored during treatment with Thymoglobulin and during the transplant hospitalization. Additional subject monitoring occurs at Months 1, 3, 6 and 12 following the transplant.

Approximately 150 study subjects from 15-20 transplant centers in the United States will be enrolled.


Condition Intervention Phase
Renal Transplantation
Graft Rejection
Drug: Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomized, Prospective, Phase 2 Study Comparing Thymoglobulin in a Rapid Discontinuation of Corticosteroids Protocol With Standard Corticosteroid Therapy in Living Donor Renal Transplantation Using Mycophenolate Mofetil and Tacrolimus Maintenance Therapy

Resource links provided by NLM:


Further study details as provided by Genzyme, a Sanofi Company:

Primary Outcome Measures:
  • This study will evaluate the effect of Thymoglobulin and reduced doses of steroids to prevent renal transplant rejection, organ loss and death at 6 months.

Secondary Outcome Measures:
  • To evaluate patient kidney function after transplantation and the overall safety of Thymoglobulin in this patient population.

Estimated Enrollment: 150
Study Start Date: June 2003
Study Completion Date: December 2005
Primary Completion Date: December 2005 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult living donor renal transplant recipient
  • Age greater than or equal to 18
  • If female and of childbearing potential: a) must not be lactating; b) must have a negative serum B-human chorionic gonadotropin (HCG) test within 24 hours prior to Study Day 0 (Day of Transplant) and; c) must agree to practice an acceptable and reliable form of contraception during the study; and
  • Signed informed consent

Exclusion Criteria:

  • Human Leukocyte Antibody (HLA) identical matched living donor transplant recipient
  • > 2 previous transplants
  • Current panel reactive antibody (PRA) > 20%
  • History of a positive cross-match with the donor
  • Active donor or recipient serology positive for human immunodeficiency virus (HIV), Hepatitis B virus (HBV) or Hepatitis C virus (HCV)
  • Loss of first kidney transplant in < 1 year
  • History of noncompliance in clinical trial(s)
  • History of chronic CS or immunosuppressive use except for inhaled CS to treat asthma
  • Use of any investigational products during the 90 days prior to screening
  • Requirement for multiple organ transplant
  • Patient without a functioning urinary bladder prior to transplant (e.g. patients with self catheterization will be excluded)
  • Known contraindication to administration of rabbit antithymocyte globulin
  • Currently abusing drugs or alcohol
  • In the opinion of the investigator, at high risk for poor compliance
  • In the opinion of the investigator, has a significant medical or psychosocial problem or unstable disease state that warrants exclusion from the study. Examples of significant problems include, but are not limited to morbid obesity and severe cardiac disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00089947

Locations
United States, Arkansas
University of Arkansas for Medical Science
Little Rock, Arkansas, United States, 72205
United States, California
Keck USC School of Medicine
Los Angeles, California, United States, 90033
University of California, Los Angeles Medical Center
Los Angeles, California, United States, 90095
University of California, San Diego Medical Center
San Diego, California, United States, 92103
University of California, San Francisco
San Francisco, California, United States, 94143
California Pacific Medical Center
San Francisco, California, United States, 94115
United States, Colorado
University of Colorado Health Sciences Center
Denver, Colorado, United States, 80262
United States, Georgia
Emory University
Atlanta, Georgia, United States, 30322
United States, Indiana
Indiana University
Indianapolis, Indiana, United States, 46202
United States, Louisiana
Oschner Medical Center
New Orleans, Louisiana, United States, 70121
United States, Maryland
Johns Hopkins University Hospital
Baltimore, Maryland, United States, 21287
United States, New Jersey
Saint Barnabas Medical Center
Livingston, New Jersey, United States, 07039
United States, New York
Mount Sinai School of Medicine
New York, New York, United States, 10029
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
United States, Ohio
University of Cincinnati Medical Center
Cincinnati, Ohio, United States, 45267
Christ Hospital
Cincinnati, Ohio, United States, 45219
United States, Texas
Texas Transplant Institute
San Antonio, Texas, United States, 78229
United States, Virginia
Medical College of Virginia
Richmond, Virginia, United States, 23298
United States, Wisconsin
Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226
Sponsors and Collaborators
Genzyme, a Sanofi Company
Investigators
Study Director: Medical Monitor Genzyme, a Sanofi Company
  More Information

Additional Information:
No publications provided

Responsible Party: Medical Monitor, Genzyme Corporation
ClinicalTrials.gov Identifier: NCT00089947     History of Changes
Other Study ID Numbers: SMC-101-1025
Study First Received: August 18, 2004
Last Updated: August 10, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Genzyme, a Sanofi Company:
Anti-T cell antibodies
Living Donor Renal Transplantation
Acute Renal Allograft Rejection
Induction Therapy with Reduction of Calcineurin inhibitors

Additional relevant MeSH terms:
Antilymphocyte Serum
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Immunosuppressive Agents

ClinicalTrials.gov processed this record on September 30, 2014